MED28

Across TCGA pan-cancer cohorts, MED28 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED28 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MED28 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MED28 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where MED28 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.761	0.938	<.001	94	view →
LUAD	DFS	Tertile	III,IV	0.865	0.318	.001	36	view →
LSCC	DFS	Median	III,IV	0.919	0.456	.006	26	view →
PDAC	OS	Median	II,III,IV	0.370	0.632	.011	15	view →
COAD	DFS	Median	II,III,IV	0.874	0.981	.043	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED28–HNSC (OS)

Open the HNSC breakdown →